Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 522 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Viread Clear all

Conditions: Alzheimer's Disease
Interventions: Emtricitabine and tenofovir disoproxil fumarate combination, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 55 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV-1 Infection
Interventions: COBI, RTV, ATV, FTC/TDF, COBI placebo, RTV placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 31
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 23 more

Conditions: HIV Infection
Interventions: Tenofovir DF; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Hepatitis B
Interventions: TDF, ADV, TDF placebo, ADV placebo, FTC/TDF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 20
States / cities: Orange, California • Pasadena, California • San Diego, California + 14 more

Conditions: HIV/AIDS, PrEP
Interventions: PrEP screening program, PrEP starter pack; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Atazanavir, Didanosine (enteric-coated), Efavirenz, Emtricitabine, Emtricitabine/Tenofovir disoproxil fumarate, Lamivudine/Zidovudine; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 1,571 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 27
States / cities: Los Angeles, California • Torrance, California • Denver, Colorado + 16 more

Conditions: HIV
Interventions: dolutegravir, Triumeq, Truvada; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Healthy Volunteers
Interventions: Tenofovir alafenamide, Rifapentine, Isoniazid (INH), Pyridoxine; Drug · Dietary Supplement
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Truvada (tenofovir DF + emtricitabine), Emtriva (emtricitabine), Viread (tenofovir DF); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 4
States / cities: Fort Lauderdale, Florida • Vero Beach, Florida • Baltimore, Maryland + 1 more

Conditions: HIV-1 Infection
Interventions: Emtricitabine/rilpivirine/tenofovir disoproxil fumarate; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 19
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 14 more

Conditions: HIV-1 Infection, HCV Infection
Interventions: E/C/F/TAF, F/R/TAF, LDV/SOF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more

Conditions: HIV Infections
Interventions: Tenofovir DF, Tenofovir alafenamide; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 3
States / cities: Palo Alto, California • Chicago, Illinois • New York, New York

Conditions: Body Weight Changes, Human Immunodeficiency Virus, ART, Obesity, Minority Health, BMD, Metabolic Syndrome, Fasting
Interventions: DOR/3TC/TDF, DOR + FTC/TAF, BIC/FTC/TAF; Drug · Combination Product
Lead sponsor: Prism Health North Texas; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Human Immunodeficiency Virus Infection
Interventions: darunavir with ritonavir and fixed-dose viread+emtricitabine daily; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 21 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Human Immunodeficiency Virus, Virus Shedding
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hepatitis B
Interventions: TDF, FTC/TDF, TDF Placebo, FTC/TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 3
States / cities: Bradenton, Florida • Flushing, New York • Philadelphia, Pennsylvania

Conditions: HIV-DDI
Interventions: Riociguat (Adempas, BAY 63-2521), ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, Antiretroviral protease inhibitor; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Orlando, Florida • Boston, Massachusetts

Conditions: HIV Infections, Substance Use Disorders
Interventions: PrEPsteps, Digital pill, Truvada; Behavioral · Device · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boylston, Massachusetts

Conditions: HIV Infections
Interventions: Single dose of Genvoya® and a single 800 mg dose of Darunavir®; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV, STI
Interventions: PrEP discontinuation intervention, Offering of on-demand oral PrEP, Offering of STI PEP, Injectable PrEP; Behavioral · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV-1 Infection
Interventions: FTC/RPV/TDF, EFV/FTC/TDF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 799 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 83
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 59 more

Conditions: HIV Infections
Interventions: Atazanavir, Darunavir, Efavirenz, Nevirapine, Ritonavir, Tenofovir disoproxil fumarate, Pharmacokinetic Study; Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 8 Years to 17 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 21
States / cities: Alhambra, California • La Jolla, California • Long Beach, California + 16 more

Conditions: HIV-1-infection
Interventions: PrEPsmart mobile app, Truvada; Device · Drug
Lead sponsor: Public Health Foundation Enterprises, Inc.; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Tenofovir disoproxil fumarate; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 0 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 19
States / cities: Berkeley, California • Los Angeles, California • San Francisco, California + 16 more

Search by objective public record fields.

Repurposing a Combination Antiretroviral Drug Therapy to Target Retrotransposons and Treat Early Alzheimer's Disease

Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Tenofovir Disoproxil Fumarate to Treat Pediatric HIV

A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B

Pre-Exposure Prophylaxis in the Emergency Department

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

Dolutegravir in Reservoirs

Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)

Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients

FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients

Doravirine and Weight Gain in Antiretroviral Naive

Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART

The Compartmental Biology of HIV in the Male Genital Tract

Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine

Interaction With HIV Antiretroviral Agents

Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)

Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis.

Parrying the Pitfalls of PrEP: Project PEACH

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children

PrEPsmart 2-1-1 Pilot

The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients